A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Status:
Recruiting
Trial end date:
2033-02-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to measure how well abemaciclib works in participants with
early breast cancer who are taking hormone therapy after surgery. Participants must have
breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive
(HER2+). Your participation could last up to 10 years depending on how you and your tumor
respond.